Back to news

Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing

Globe Newswire•18/11/2026•18:03 ET
2

Key Highlights

  • ➤FDA approves Regeneron’s Livsayis for anti-AChR-positive generalized myasthenia gravis
  • ➤Livsayis is first approved siRNA therapy and only quarterly subcutaneous gMG treatment
  • ➤NIMBLE showed 2.3-point placebo-adjusted MG-ADL improvement at 24 weeks
  • ➤NIMBLE showed 2.8-point placebo-adjusted QMG improvement at 24 weeks
  • ➤Livsayis carries a boxed warning for serious meningococcal infections and requires REMS

Expert Statements

Tuan Vu, Professor of Neurology, University of South Florida Morsani College of Medicine, and global principal investigator of the NIMBLE trial

“In the Phase 3 NIMBLE trial, Livsayis delivered rapid, deep disease control – maintained through the end of dosing intervals – and offers a four-times-a-year subcutaneous dosing schedule. These results highlight how a first-of-its-kind approach can address a key driver of disease and provide a compelling treatment option.”

George D. Yancopoulos, Board Co-Chair, President and Chief Scientific Officer of Regeneron

“Livsayis is Regeneron’s first approved medicine in neurology, and an important new option for people living with generalized myasthenia gravis who need effective disease control without a heavy treatment burden.”

George D. Yancopoulos, Board Co-Chair, President and Chief Scientific Officer of Regeneron

“As Regeneron’s first approved siRNA therapy, this approval marks a meaningful step forward for our neuroscience pipeline as we relentlessly pursue bold, new approaches to transform care for people living with serious neurological diseases.”

Samantha Masterson, President & CEO, Myasthenia Gravis Foundation of America

“This approval is a positive milestone for the gMG community, reflecting continued progress on outcomes that matter most to patients. With Livsayis, those living with generalized myasthenia gravis have a new option that may help maintain disease control while reducing the burden treatment can place on daily life.”

Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing intervals

Livsayis is Regeneron's first approved siRNA therapy and neurology medicine

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in